Medpace forecasts solid Q3 2025 revenue and earnings amid expanding clinical research demand

Medpace Holdings (MEDP) expects Q3 2025 revenue of $641 million and earnings per share of approximately $3.57, supported by robust contract research demand across pharma and biotech clients. For the full year, management projects revenue between $2.42 billion and $2.52 billion with EBITDA ranging from $515 million to $545 million. Growth is driven by new trial awards in oncology and rare diseases and improved client retention. The company emphasized operational discipline and capacity expansion in Asia and Europe. Analysts expect continued margin stability due to automation in data management and enhanced regulatory efficiency.